Advertisement

Ads Placeholder
Loading...

Sundrug Co.,Ltd.

SDGCFPNK
Healthcare
Medical - Pharmaceuticals
$28.18
$0.00(0.00%)
U.S. Market opens in 50h 42m

Sundrug Co.,Ltd. Fundamental Analysis

Sundrug Co.,Ltd. (SDGCF) shows moderate financial fundamentals with a PE ratio of 16.83, profit margin of 3.73%, and ROE of 11.41%. The company generates $837.1B in annual revenue with moderate year-over-year growth of 6.66%.

Key Strengths

Cash Position2125.99%
PEG Ratio-0.06
Current Ratio1.72

Areas of Concern

Operating Margin5.54%
We analyze SDGCF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 47.7/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
47.7/100

We analyze SDGCF's fundamental strength across five key dimensions:

Efficiency Score

Weak

SDGCF struggles to generate sufficient returns from assets.

ROA > 10%
6.64%

Valuation Score

Excellent

SDGCF trades at attractive valuation levels.

PE < 25
16.83
PEG Ratio < 2
-0.06

Growth Score

Moderate

SDGCF shows steady but slowing expansion.

Revenue Growth > 5%
6.66%
EPS Growth > 10%
5.56%

Financial Health Score

Excellent

SDGCF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.18
Current Ratio > 1
1.72

Profitability Score

Weak

SDGCF struggles to sustain strong margins.

ROE > 15%
11.41%
Net Margin ≥ 15%
3.73%
Positive Free Cash Flow
No

Key Financial Metrics

Is SDGCF Expensive or Cheap?

P/E Ratio

SDGCF trades at 16.83 times earnings. This indicates a fair valuation.

16.83

PEG Ratio

When adjusting for growth, SDGCF's PEG of -0.06 indicates potential undervaluation.

-0.06

Price to Book

The market values Sundrug Co.,Ltd. at 1.89 times its book value. This may indicate undervaluation.

1.89

EV/EBITDA

Enterprise value stands at 8.50 times EBITDA. This is generally considered low.

8.50

How Well Does SDGCF Make Money?

Net Profit Margin

For every $100 in sales, Sundrug Co.,Ltd. keeps $3.73 as profit after all expenses.

3.73%

Operating Margin

Core operations generate 5.54 in profit for every $100 in revenue, before interest and taxes.

5.54%

ROE

Management delivers $11.41 in profit for every $100 of shareholder equity.

11.41%

ROA

Sundrug Co.,Ltd. generates $6.64 in profit for every $100 in assets, demonstrating efficient asset deployment.

6.64%

Following the Money - Real Cash Generation

Operating Cash Flow

Sundrug Co.,Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

Sundrug Co.,Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

SDGCF converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

16.83

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.06

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.89

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.63

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.18

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.72

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.11

vs 25 benchmark

ROA

Return on assets percentage

0.07

vs 25 benchmark

ROCE

Return on capital employed

0.14

vs 25 benchmark

How SDGCF Stacks Against Its Sector Peers

MetricSDGCF ValueSector AveragePerformance
P/E Ratio16.8328.45 Better (Cheaper)
ROE11.41%763.00% Weak
Net Margin3.73%-45265.00% (disorted) Weak
Debt/Equity0.180.34 Strong (Low Leverage)
Current Ratio1.722795.60 Neutral
ROA6.64%-16588.00% (disorted) Weak

SDGCF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sundrug Co.,Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

29.72%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

29.72%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

27.48%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ